If you have been reading about Nicotinamide mononucleotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-18. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
=== Features that promote de novo gene birth === Its also of interest to compare features of recently emerged de novo genes to the pool of non-genic ORFs from which they emerge. Theoretical modeling has shown that such differences are the product both of selection for features that increase the likelihood of functionalization, and of neutral evolutionary forces that influence allelic turnover. In budding yeast, systematic deletion and overexpression assays of newly emerged ORFs found that overexpression is enriched for fitness benefits, and that adaptive emerging sequences are biased toward encoding transmembrane domains from thymine-rich intergenic regions. One proposed route to de novo membrane proteins is that poly-A–rich sequences can generate hydrophobic ORFs that are predicted to form transmembrane helices. Across Saccharomycotina yeasts, intergenic regions show widespread enrichment for putative transmembrane-domain encoding potential, and this enrichment (rather than raw hydrophobicity alone) correlates with the abundance of transmembrane domains in evolutionarily young genes. Laboratory studies comparing young de novo proteins to matched unevolved random-sequence proteins found broadly similar predicted biophysical-property distributions, but moderately higher in vitro solubility for de novo proteins (further increased by the DnaK chaperone system). High-throughput sorting of thousands of putative human de novo sORF-encoded proteins by structural compactness showed that older candidates are, on average, more compact and less disordered than younger ones.
=== Implant-pocket placement === The four surgical approaches for the emplacement of a prosthetic breast into the implant-pocket are described in anatomical relation to the pectoralis major muscle, the major muscle of the chest.
Trials are investigating whether botulinum toxin, when used to make a person appear to frown less, stops negative feedback from the face and affects depression. Psilocybin may have a beneficial role in the treatment of depression. A 2019 meta-analysis found that hypnotherapy may be an effective way of alleviating the symptoms of depression. No model of depression in animals that fully explains the mechanism of depression has been found as of 2019.
Turquoise was among the first gems to be mined, and many historic sites have been depleted, though some are still worked to this day. These are all small-scale operations, often seasonal owing to the limited scope and remoteness of the deposits. Most are worked by hand with little or no mechanization. However, turquoise is often recovered as a byproduct of large-scale copper mining operations, especially in the United States.
Sources: en.wikipedia.org
=== Type I === A civilization "close to the level currently achieved on Earth, with an energy consumption of ≈4×1019 erg/s" (≈4×1012 watts). A Type I civilization is usually defined as one that can harness all the energy that reaches its home planet from its parent star (for Earth, this value is about 2×1017 watts), which is about four orders of magnitude higher than the amount currently achieved on Earth, with an energy consumption of ≈2×1013 watts by 2020. The astronomer Guillermo A. Lemarchand defined Type I as a level close to today's terrestrial civilization, with an energy capacity equivalent to Earth's solar irradiance, between 1016 and 1017 watts.
== Research == Treatment of sarcoma, especially when the sarcoma has spread, or "metastasized", often requires chemotherapy. However, existing chemotherapeutic medicines are associated with significant toxicities and are not highly effective in killing cancer cells. Therefore, research to identify new medications to treat sarcoma is being conducted as of 2019. One new type of therapy still under investigation is the use of cancer immunotherapy (e.g., immune checkpoint inhibitors like anti-PD1, anti-PDL1, and anti-CTLA4 agents) to treat sarcomas. These drugs are not yet FDA- or other regulator-approved treatment, except PDL1 inhibitor atezolizumab for the ultra-rate diagnosis of alveolar soft part sarcoma. Other strategies, such as small-molecule targeted therapy, biologic agents (e.g., small interfering RNA molecules), and nanoparticle-directed therapy, also are under active investigation. Research to understand the specific genetic and molecular factors that cause sarcoma to develop is underway. This could allow for the design of new targeted therapies and allow physicians to more accurately predict a patient's prognosis. However, due to rarity of sarcomas, as well as sarcoma-specific characteristics (e.g. more common invasion via cardiovascular system), research may be particularly challenging in both clinical and preclinical models. Research by Clinician Scientist of University of British Columbia Torsten O. Nielsen has contributed to advances in the molecular understanding and classification of sarcoma, particularly soft tissue subtypes.
== In leukocytes == A group of leukocytes, called granulocytes, are white blood cells containing enzyme granules that play a significant role in the immune system. Granulocytes include neutrophils, eosinophils, and basophils which attack bacteria or parasites, and respond to allergens. Each type of granulocyte contains enzymes and chemicals tailored to its function. Neutrophils for example, contain primary granules, secondary granules, tertiary granules, and secretory vesicles. Primary vesicles, also known as azurophilic granules, secrete hydrolytic enzymes including elastase, myeloperoxidase, cathepsins, and defensins that aid in pathogen destruction. Secondary granules, or specific granules, in neutrophils contain iron-binding protein lactoferrin. Tertiary granules contain matrix metalloproteinases. Other immune cells, such as natural killer cells, contain granular enzymes, including perforin and proteases which can lead to the lysis of neighboring cells. The process by which granule contents are released is known as degranulation. This tightly controlled process is initiated by immunological stimuli and results in the movement of granules to the cell membrane for fusion and release.
== History == The disease was described in 1933 by Henrik Sjögren, after whom it is named, but several earlier descriptions of people with the symptoms exist. Jan Mikulicz-Radecki (1850–1905) is generally credited with the first description of Sjögren’s. In 1892, he described a 42-year-old man with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. However, the criteria that Mikulicz established for diagnosis often led to misdiagnosis of Mikulicz's syndrome. Many conditions, such as tuberculosis, infections, sarcoidosis, and lymphoma, present with similar conditions to those ascribed to Mikulicz's syndrome. Nevertheless, the term "Mikulicz's syndrome" is still used occasionally to describe the appearance of lymphocytic infiltrates on salivary-gland biopsies. In 1930, Henrik Sjögren (1899–1986), an ophthalmologist in Jönköping, Sweden, observed a patient with low secretions from the lacrimal and salivary glands. Sjögren introduced the term keratoconjunctivitis sicca for the symptom of dry eyes (keratoconjunctivitis). In 1933, he published his doctoral thesis describing 19 females, most of whom were postmenopausal and had arthritis, showing clinical and pathological manifestations of the syndrome. Sjögren clarified that keratoconjunctivitis sicca, resulting from water deficiency, had no relation to xerophthalmia, resulting from vitamin A deficiency. Sjögren's thesis was not well received as the Board of Examiners criticized some clinical aspects.
== Anatomy == The pulp is the neurovascular bundle central to each tooth, permanent or primary. It is composed of a central pulp chamber, pulp horns, and radicular canals. The large mass of the pulp is contained within the pulp chamber, which is contained in and mimics the overall shape of the crown of the tooth. Because of the continuous deposition of the dentine, the pulp chamber becomes smaller with the age. This is not uniform throughout the coronal pulp but progresses faster on the floor than on the roof or sidewalls. Radicular pulp canals extend down from the cervical region of the crown to the root apex. They are not always straight but vary in shape, size, and number. They are continuous with the periapical tissues through the apical foramen or foramina. The total volume of all the permanent teeth organs is 0.38cc, and the mean volume of a single adult human pulp is 0.02cc. Accessory canals are pathways from the radicular pulp. These canals, which extend laterally through the dentin to the periodontal tissue, are seen especially in the apical third of the root. Accessory canals are also called lateral canals because they are usually located on the lateral surface of the roots of the teeth.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.